Would you recommend starting a moderate-intensity statin in a patient under the age of 40 years old with HIV and a 10-year ASCVD risk estimate below 5%?
The REPRIEVE trial included participants who were between 40 and 75 years old.
Answer from: at Community Practice
I am impressed by the benefit of statins in HIV patients but wonder if the benefit is affected by viral load (which may cause generalized inflammation and/or immune activation).
I have not yet reached the point where I am ready to put low-risk, non-hypercholesteremic HIV patients on statins, but am...